B-Cell Lymphoma Clinical Trials

• Male or female subject aged ≥ 18 years.

• Pathologically confirmed B-cell lymphoma patients intended for standard of care CAR-T

• ECOG Performance Status ≤ 2.

• Subjects must be clinically eligible to receive standard of care anti-CD19 CAR-T

• Subjects must have at least one site of disease amenable to radiation, with the ability to deliver radiation to at least 50% of involved sites

• Subjects must have at least one site of measurable disease based on CT or FDG PET

• Subjects must not be anticipated to require additional therapy beyond bridging radiation listed in this protocol for control of their lymphoma

• For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause.

⁃ The following age-specific requirements apply:

⁃ Women \< 50 years of age: amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).

⁃ Women ≥ 50 years of age: amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or had radiation-induced menopause with last menses \>1 year ago; or had chemotherapy-induced menopause with last menses \>1 year ago; or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).

• Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

• Stated willingness to comply with all study procedures and availability for the duration of the study